Design, synthesis, and in vitro and in vivo biological evaluation of 2-amino-naphtho[2,3-b]thiophene-4,9-dione derivatives as potent anticancer agents.
Soumen K. Manik, Satyajit Haldar, Ankita Bhattachrya, Utsab Debnath, Sk Asraf Ali, Shraman Jana, Manik Shit, Pallab K. Haldar, Suniti Pradhan, Dipak K. Hazra, Kankan K. Maity, Sudipta Kumar Ghorai, Shubhankar Samanta, Anup K. Misra, Kuladip Jana, Nirmal K. Hazra
{"title":"Design, synthesis, and in vitro and in vivo biological evaluation of 2-amino-naphtho[2,3-b]thiophene-4,9-dione derivatives as potent anticancer agents.","authors":"Soumen K. Manik, Satyajit Haldar, Ankita Bhattachrya, Utsab Debnath, Sk Asraf Ali, Shraman Jana, Manik Shit, Pallab K. Haldar, Suniti Pradhan, Dipak K. Hazra, Kankan K. Maity, Sudipta Kumar Ghorai, Shubhankar Samanta, Anup K. Misra, Kuladip Jana, Nirmal K. Hazra","doi":"10.1016/j.ejmech.2025.117728","DOIUrl":null,"url":null,"abstract":"This study synthesized a series of substituted 2-amino-naphtho[2,3-b]thiophene 4,9-dione derivatives through multi-component reactions involving Domino and Krapcho strategies. Among the 15 synthesized analogs, compound <strong>4a</strong> emerged as a lead compound with potent anticancer activity against the aggressive triple-negative breast cancer (TNBC) cell line MDA-MB-231. Mechanistic investigations demonstrated that treatment with compound <strong>4a</strong> induced dose-dependent inhibition of cell viability, cell cycle arrest, and robust apoptotic responses in MDA-MB-231 cells. Apoptotic assays confirmed enhanced caspase-3/7 activation and increased reactive oxygen species (ROS) generation. Crucially, immunocytochemistry analysis revealed that compound <strong>4a</strong> significantly suppressed the phosphorylation of Akt at Ser473, a pivotal regulatory event in the PI3K/Akt signaling pathway, which is frequently dysregulated in TNBC. This inhibition disrupted pro-survival signaling, sensitizing MDA-MB-231 cells to apoptosis while sparing normal cells, highlighting compound <strong>4a</strong> as a potential anticancer agent through selective therapeutic targeting of Akt-driven pathways.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"125 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.117728","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
This study synthesized a series of substituted 2-amino-naphtho[2,3-b]thiophene 4,9-dione derivatives through multi-component reactions involving Domino and Krapcho strategies. Among the 15 synthesized analogs, compound 4a emerged as a lead compound with potent anticancer activity against the aggressive triple-negative breast cancer (TNBC) cell line MDA-MB-231. Mechanistic investigations demonstrated that treatment with compound 4a induced dose-dependent inhibition of cell viability, cell cycle arrest, and robust apoptotic responses in MDA-MB-231 cells. Apoptotic assays confirmed enhanced caspase-3/7 activation and increased reactive oxygen species (ROS) generation. Crucially, immunocytochemistry analysis revealed that compound 4a significantly suppressed the phosphorylation of Akt at Ser473, a pivotal regulatory event in the PI3K/Akt signaling pathway, which is frequently dysregulated in TNBC. This inhibition disrupted pro-survival signaling, sensitizing MDA-MB-231 cells to apoptosis while sparing normal cells, highlighting compound 4a as a potential anticancer agent through selective therapeutic targeting of Akt-driven pathways.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.